Read this company snapshot
Daily valuation snapshot
Aptevo Therapeutics Inc: source evidence dated 2026-10-09.
- Daily close (USD)
- $1.79
- Market capitalization (USD)
- $3,225,526.3
- Price / earnings (TTM)
- Not reported
- Price / book
- 0.53
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research APVO in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research APVO in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing APVO with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $1.79 |
| Market capitalization (USD) | $3,225,526.3 |
| Price / earnings (TTM) | Not reported |
| Price / book | 0.53 |
No matching rows. Clear the filter to see all records.
Read APVO's valuation metrics
Company size
Aptevo Therapeutics Inc's recorded market capitalization is $3,225,526.3. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
APVO's recorded price-to-book ratio is 0.53. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Aptevo Therapeutics Inc with Aurora
Use the snapshot above to ask a specific question about APVO. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow APVO's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.